US FDA calls foul on Abbott for Kaletra promotional video
This article was originally published in Scrip
Executive Summary
A promotional video for Abbott's antiretroviral Kaletra (lopinavir plus ritonavir) minimises the drug's risks, overstates its efficacy and includes unsubstantiated claims, the US FDA's division of drug marketing, advertising and communications (DDMAC) said in a warning letter to the company.